12:00 AM
 | 
Mar 09, 2009
 |  BC Week In Review  |  Company News  |  Deals

Alloksys, Cevec, PharmaCell deal

The partners will use Cevec's human CAP cell line to develop a recombinant human alkaline phosphatase (rhuAP) protein to treat chronic diseases, including rheumatoid arthritis. Cevec will develop...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >